An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)

Therapeutic Advances in Endocrinology and Metabolism

Volumn 2, Issue 5, 2011, Pages 211-225

  Lomonaco, Romina ^a   Chen, Janet ^b   Cusi, Kenneth ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

diabetes; fatty liver; insulin resistance; nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; EXENDIN 4; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN;

CARDIOVASCULAR DISEASE; DIET THERAPY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOGRAPHY; ENDOCRINOLOGY; EXERCISE; FATTY LIVER; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER TOXICITY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; WEIGHT REDUCTION;

EID: 83755196306     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018811419157     Document Type: Review

References (144)

1. Adams L.A. Lymp J.F. St Sauver J. Sanderson S.O. Lindor K.D. Feldstein A. et al (2005 a) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113–121.
2. Adams L.A. Sanderson S. Lindor K.D. Angulo P. (2005 b) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42: 132–138.
3. Adiels M. Taskinen M.-R. Boren J. (2008) Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 8: 60–64.
4. Adiels M. Taskinen M.-R. Packard C. Caslake M.J. Soro-Paavonen A. Westerbacka J. et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49: 755–755.
5. Aithal G.P. Thomas J.A. Kaye P.V. Lawson A. Ryder S.D. Spendlove I. et al (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135: 1176–1184.
6. Ali R. Cusi K. (2009) New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 41: 265–278.
7. Andersen T. Gluud C. Franzmann M.B. Christoffersen P. (1991) Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12: 224–229.
8. Angulo P. Hui J.M. Marchesini G. Bugianesi E. George J. Farrell G.C. et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45: 846–854.
9. Argo C.K. Loria P. Caldwell S.H. Lonardo A. (2008) Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48: 662–669.
10. Backman J.T. Kyrklund C. Kivisto K.T. Wang J.S. Neuvonen P.J. (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68: 122–129.
11. Backman J.T. Kyrklund C. Kivisto K.T. Wang J.S. Neuvonen P.J. (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68: 122–129.
12. Bataller R. Rombouts K. Altamirano J. Marra F. (2011) Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 25: 231–244.
13. Belfort R. Berria R. Cornell J. Cusi K. (2010) Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 95: 829–836.
14. Belfort R. Harrison S.A. Brown K. Darland C. Finch J. Hardies J. et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297–2307.
15. Bergman A.J. Murphy G. Burke J. Zhao J.J. Valesky R. Liu L. et al (2004) Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 44: 1054–1062.
16. Browning J.D. (2006) Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 44: 466–471.
17. Browning J.D. Kumar K.S. Saboorian M.H. Thiele D.L. (2004a) Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99: 292–298.
18. Browning J.D. Szczepaniak L.S. Dobbins R. Nuremberg P. Horton J.D. Cohen J.C. et al (2004b) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387–1395.
19. Bugianesi E. Gentilcore E. Manini R. Natale S. Vanni E. Villanova N. et al (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100: 1082–1090.
20. Bugianesi E. Vanni E. Marchesini G. (2007) NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep 7: 175–180.
21. Caldwell S. (2010) Cryptogenic cirrhosis: what are we missing? Curr Gastroenterol Rep 12: 40–48.
22. Centers for Disease Control and Prevention (2011) National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011 US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA.
23. Chalasani N. (2005) Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 41: 690–695.
24. Chavez-Tapia N.C. Tellez-Avila F.I. Barrientos-Gutierrez T. Mendez-Sanchez N. Lizardi-Cervera J. Uribe M. (2010) Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 1: CD007340–CD007340.
25. Chitturi S. Wong V.W. Farrell G. (2011) Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 26(Suppl. 1): 163–172.
26. Clark J.M. Brancati F.L. Diehl A.M. (2002) Nonalcoholic fatty liver disease. Gastroenterology 122: 1649–1657.
27. Clark J.M. Brancati F.L. Diehl A.M. (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98: 960–967.
28. Cohen D.E. Anania F.A. Chalasani N. (2006) An assessment of statin safety by hepatologists. Am J Cardiol 97(8A): 77C–81C.
29. Cowin G.J. Jonsson J.R. Bauer J.D. Ash S. Ali A. Osland E.J. et al (2008) Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 28: 937–945.
30. Csendes A. Smok G. Burgos A.M. (2006) Histological findings in the liver before and after gastric bypass. Obes Surg 16(5): 607–611.
31. Cusi K. (2009a) Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16: 141–149.
32. Cusi K. (2009b) Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis 13: 545–563.
33. Cusi K. (2009c) The epidemic of type 2 diabetes mellitus: its links to obesity, insulin resistance and lipotoxicity. In Judith Regensteiner, Jane Reusch, Kerry Stewart and Aris Veves (eds.) Textbook of Diabetes and Exercise, Humana Press Inc pp 3–54.
34. Cusi K. (2010) The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep 10: 306–315.
35. Cusi K. (2011) Clinical implications of obesity and lipotoxicity for the treatment of nonalcoholic steatohepatitis (NASH). Gastroenterology in press.
36. Cusi K. Chang Z. Harrison S. Lomonaco R. Ortiz-Lopez C. Feldstein A. et al (2011) Relationship of cytokeratin-18 with clinical, metabolic and histological parameters in patients with nonalcoholic steatohepatitis (NASH). Hepatology in press.
37. Cusi K. Consoli A. DeFronzo R.A. (1996) Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81: 4059–4067.
38. Cusi K. DeFronzo R. (1998) Metformin: a review of its metabolic effects. Diabetes Reviews 6: 89–131.
39. DeFronzo R.A. Tripathy D. Schwenke D.C. Banerji M. Bray G.A. Buchanan T.A. et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364: 1104–1115.
40. Diab D.L. Yerian L. Schauer P. Kashyap S.R. Lopez R. Hazen S.L. et al (2008) Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 6: 1249–1254.
41. Ding X. Saxena N.K. Lin S. Gupta N.A. Anania F.A. (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173–181.
42. Dowman J.K. Tomlinson J.W. Newsome P.N. (2011) Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 33: 525–540.
43. Duseja A. (2010) Nonalcoholic fatty liver disease in India - a lot done, yet more required!. Indian J Gastroenterol 29: 217–225.
44. Duseja A. Das A. Dhiman R.K. Chawla Y.K. Thumburu K.T. Bhadada S. et al (2007) Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 6: 222–226.
45. Ekstedt M. Franzen L.E. Mathiesen U.L. Holmqvist M. Bodemar G. Kechagias S. (2007) Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 47: 135–141.
46. Ekstedt M. Franzen L.E. Mathiesen U.L. Thorelius L. Holmqvist M. Bodemar G. et al (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865–873.
47. Fassio E. Alvarez E. Dominguez N. Landeira G. Longo C. (2004) Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40: 820–826.
48. Feldstein A.E. Wieckowska A. Lopez A.R. Liu Y.C. Zein N.N. McCullough A.J. (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50: 1072–1078.
49. Fernandez-Miranda C. Perez-Carreras M. Colina F. Lopez-Alonso G. Vargas C. Solis-Herruzo J.A. (2008) A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 40: 200–205.
50. Fogelholm M. (2010) Physical activity, fitness and fatness: relations to mortality, morbidity and disease risk factors. A systematic review. Obes Rev 11: 202–221.
51. Fracanzani A.L. Valenti L. Bugianesi E. Andreoletti M. Colli A. Vanni E. et al (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48: 792–798.
52. Fraser A. Thinggaard M. Christensen K. Lawlor D.A. (2009) Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all-cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver Int 29: 1494–1499.
53. Friedrich-Rust M. Ong M.F. Martens S. Sarrazin C. Bojunga J. Zeuzem S. et al (2008) Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134: 960–974.
54. Gaia S. Carenzi S. Barilli A.L. Bugianesi E. Smedile A. Brunello F. et al (2011) Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 54: 64–71.
55. Gastaldelli A. Harrison S. Belfort-Aguiar R. Hardies J. Balas B. Schenker S. et al (2010) Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 32: 769–775.
56. Ginsberg H.N. Elam M.B. Lovato L.C. Crouse III.J.R. Leiter L.A. Linz P. et al (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563–1574.
57. Gregor M. Hotamisligil G. (2007) Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 48: 1905–1914.
58. Harrison S.A. (2006) Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 40: 68–76.
59. Harrison S.A. Fecht W. Brunt E.M. Neuschwander-Tetri B.A. (2009) Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 49: 80–86.
60. Harrison S.A. Torgerson S. Hayashi P.H. (2003) The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98: 2042–2047.
61. Haufe S. Engeli S. Kast P. Bohnke J. Utz W. Haas V. et al (2011) Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 53: 1504–1514.
62. Haukeland J.W. Konopski Z. Eggesbo H.B. von Volkmann H.L. Raschpichler G. Bjoro K. et al (2009) Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44: 853–860.
63. Hickman I.J. Jonsson J.R. Prins J.B. Ash S. Purdie D.M. Clouston A.D. et al (2004) Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53: 413–419.
64. Kankaanpaa M. Lehto H.-R. Parkka J. Komu M. Viljanen A. (2006) Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol 91: 4689–4695.
65. Kantartzis K. Thamer C. Peter A. Machann J. Schick F. Schraml C. et al (2009) High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58: 1281–1288.
66. Kashyap R. Belfort Cersosimo E. Lee S. Cusi K. (2008) Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects. J Cardiometabol Syndrome 3: 141–146.
67. Keech A. Simes R.J. Barter P. Best J. Scott R. Taskinen M.R. et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861.
68. Kenny P.R. Brady D.E. Torres D.M. Ragozzino L. Chalasani N. Harrison S.A. (2010) Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 105: 2707–2709.
69. Kirk E. Reeds D.N. Finck B.N. Mayurranjan S.M. Patterson B.W. Klein S. (2009) Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 136: 1552–1560.
70. Kotronen A. Juurinen L. Hakkarainen A. Westerbacka J. Corner A. Bergholm R. et al (2008) Liver fat Is Increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31: 165–169.
71. Kugelmas M. Hill D.B. Vivian B. Marsano L. McClain C.J. (2003) Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38: 413–419.
72. Larson-Meyer D.E. Heilbronn L.K. Redman L.M. Newcomer B.R. Frisard M.I. Anton S. et al (2006) Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 29: 1337–1344.
73. Larson-Meyer D.E. Newcomer B.R. Heilbronn L.K. Volaufova J. Smith S.R. Alfonso A.J. et al (2008) Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 16: 1355–1362.
74. Lavine J.E. Schwimmer J.B. Van Natta M.L. Molleston J.P. Murray K.F. Rosenthal P. et al (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305: 1659–1668.
75. Lazo M. Solga S.F. Horska A. Bonekamp S. Diehl A.M. Brancati F.L. et al (2010) Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 33: 2156–2163.
76. Leite N.C. Villela-Nogueira C.A. Pannain V.L. Bottino A.C. Rezende G.F. Cardoso C.R. et al (2011) Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 31: 700–706.
77. Lewis J.H. Mortensen M.E. Zweig S. Fusco M.J. Medoff J.R. Belder R. (2007) Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46: 1453–1463.
78. Liang R.J. Wang H.H. Lee W.J. Liew P.L. Lin J.T. Wu M.S. (2007) Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 17: 45–56.
79. Lomonaco R. Ortiz-Lopez C. Orsak B. Finch J. Webb A. Bril F. et al (2011a) Role of ethnicity in overweight and obese subjects with nonalcoholic steatohepatitis (NASH). Hepatology in press doi: 10.1002/hep.24483.
80. Lomonaco R. Orsak B. Ortiz-Lopez C. Chen J. Webb A. Cusi K. (2011b) Effect of liver fat accumulation on insulin resistance and severity of NASH in obese patients with T2DM. Diabetes 60: A1668–A1668.
81. Longo R. Pollesello P. Ricci C. Masutti F. Kvam B.J. Bercich L. et al (1995) Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 5: 281–285.
82. Loomba R. Lutchman G. Kleiner D.E. Ricks M. Feld J.J. Borg B.B. et al (2009) Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 29: 172–182.
83. Marchesini G. Brizi M. Bianchi G. Tomassetti S. Zoli M. Melchionda N. (2001) Metformin in non-alcoholic steatohepatitis. Lancet 358: 893–894.
84. Marchesini G. Bugianesi E. Forlani G. Cerrelli F. Lenzi M. Manini R. et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917–923.
85. Mathew M. Tay E. Cusi K. (2010) Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 9: 9–9.
86. Mathurin P. Hollebecque A. Arnalsteen L. Buob D. Leteurtre E. Caiazzo R. et al (2009) Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137: 532–540.
87. Mazhar S.M. Shiehmorteza M. Sirlin C.B. (2009) Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 7: 135–140.
88. McGavock J. Victor R. Unger R. Szczepaniak L. (2006) Adiposity of the heart, revisited. Ann Intern Med 144: 517–524.
89. McKenney J.M. Davidson M.H. Jacobson T.A. Guyton J.R. (2006) Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97(8A): 89C–94C.
90. Mencin A.A. Lavine J.E. (2011) Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 14: 151–157.
91. Mofrad P. Contos M.J. Haque M. Sargeant C. Fisher R.A. Luketic V.A. et al (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37: 1286–1292.
92. Mohanty S.R. Troy T.N. Huo D. O'Brien B.L. Jensen D.M. Hart J. (2009) Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 50: 797–804.
93. Muhlhausler B. Smith S.R. (2009) Early-life origins of metabolic dysfunction: role of the adipocyte. Trends Endocrinol Metab 20: 51–57.
94. Musso G. Gambino R. Cassader M. Pagano G. (2010) Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med in press.
95. Nair S. Diehl A.M. Wiseman M. Farr G.H. Jr Perrillo R.P. (2004) Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20: 23–28.
96. Neuschwander-Tetri B.A. Clark J.M. Bass N.M. Van Natta M.L. Unalp-Arida A. Tonascia J. et al (2010) Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52: 913–924.
97. Okita M. Hayashi M. Sasagawa T. Takagi K. Suzuki K. Kinoyama S. et al (2001) Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition 17: 542–547.
98. Orsi C. Matthew M. Chen J. Darland J. Gastaldelli A. Ali R. et al (2009) Adding exenatide to bedtime insulin detemir promotes weight loss and improves hepatic steatosis in insulin-treated patients with T2DM. Diabetologia 52(Suppl. 1): A248–A248.
99. Ortiz-Lopez C. Orsak B. Darland C. Finch J. Lomonaco R. Cusi K. (2010) Abnormal glucose metabolism is common in NASH patients and associated with more severe hepatic and adipose tissue insulin resistance and hepatocyte necroinflammation. Diabetes 59(Suppl. 1): A88–A88.
100. Ortiz-Lopez C. Orsak B. Lomonaco R. Finch J. Darland C. Cusi K. (2011) Insulin resistance but not hyperglycemia, plays a key role in the severity of NAFLD in T2DM patients. Diabetes 60(Suppl. 1): A1665–A1665.
101. Pagadala M. Zein C.O. McCullough A.J. (2009) Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 13: 591–606.
102. Palmer M. Schaffner F. (1990) Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99: 1408–1413.
103. Perseghin G. Lattuada G. De Cobelli F. Esposito A. Belloni E. Ntali G. et al (2008) Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47: 51–58.
104. Petersen K.F. Dufour S. Befroy D. Lehrke M. Hendler R.E. Shulman G.I. (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54: 603–608.
105. Pillai A.A. Rinella M.E. (2009) Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis 13: 689–710.
106. Poynard T. Ratziu V. Charlotte F. Messous D. Munteanu M. Imbert-Bismut F. et al (2006) Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6: 34–34.
107. Ratziu V. Charlotte F. Bernhardt C. Giral P. Halbron M. Lenaour G. et al (2010) Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51: 445–453.
108. Ratziu V. Giral P. Jacqueminet S. Charlotte F. Hartemann-Heurtier A. Serfaty L. et al (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135: 100–110.
109. Ratziu V. Massard J. Charlotte F. Messous D. Imbert-Bismut F. Bonyhay L. et al (2006) Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6: 6–6.
110. Reingold J.S. McGavock J.M. Kaka S. Tillery T. Victor R.G. Szczepaniak L.S. (2005) Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab 289: E935–E939.
111. Riley P. Sudarshi D. Johal M. Benedict A. Panteli J. Crook M. et al (2008) Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract 62: 374–381.
112. Ryysy L. Hakkinen A.M. Goto T. Vehkavaara S. Westerbacka J. Halavaara J. et al (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49: 749–758.
113. Saadeh S. Younossi Z.M. Remer E.M. Gramlich T. Ong J.P. Hurley M. et al (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 745–750.
114. Sanyal A.J. Chalasani N. Kowdley K.V. McCullough A. Diehl A.M. Bass N.M. et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675–1685.
115. Sattar N. Scherbakova O. Ford I. O'Reilly D.S. Stanley A. Forrest E. et al (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53: 2855–2860.
116. Schafer S. Kantartzis K. Machann J. Venter C. Niess A. Schick F. et al (2007) Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest 37: 535–543.
117. Schwimmer J.B. Deutsch R. Kahen T. Lavine J.E. Stanley C. Behling C. (2006) Prevalence of fatty liver in children and adolescents. Pediatrics 118: 1388–1393.
118. Shoelson S. Lee J. Goldfine A. (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793–1801.
119. Sjostrom L. Narbro K. Sjostrom C.D. Karason K. Larsson B. Wedel H. et al (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357: 741–752.
120. Sreenivasa Baba C. Alexander G. Kalyani B. Pandey R. Rastogi S. Pandey A. et al (2006) Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 21(1 Pt 1): 191–198.
121. Suzuki A. Lindor K. St Saver J. Lymp J. Mendes F. Muto A. et al (2005) Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 43: 1060–1066.
122. Szczepaniak L.S. Babcock E.E. Schick F. Dobbins R.L. Garg A. Burns D.K. et al (1999) Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 276(5 Pt 1): E977–E989.
123. Szczepaniak L.S. Nurenberg P. Leonard D. Browning J.D. Reingold J.S. Grundy S. et al (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288: E462–E468.
124. Tamura Y. Tanaka Y. Sato F. Choi J.B. Watada H. Niwa M. et al (2005) Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90: 3191–3196.
125. Targher G. Day C.P. Bonora E. (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363: 1341–1350.
126. Tay C. Belfort R. Mathew M. Cusi K. (2006) A 2-day lipid or combined lipid-glucose infusion reproduce in healthy subjects the metabolic abnormalities seen in the metabolic syndrome. Diabetes 55(Suppl. 1): A66–A66.
127. Tenenbaum A. Motro M. Fisman E.Z. Tanne D. Boyko V. Behar S. (2005) Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165: 1154–1160.
128. Thamer C. Machann J. Stefan N. Haap M. Schafer S. Brenner S. et al (2007) High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. Obesity (Silver Spring) 15: 531–538.
129. The Diabetes Prevention Program Research Group (2005) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes 54: 2404–2414.
130. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication). Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet 368: 1096–1105.
131. Thomas E.L. Brynes A.E. Hamilton G. Patel N. Spong A. Goldin R.D. et al (2006) Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 12: 5813–5819.
132. Tiikkainen M. Bergholm R. Vehkavaara S. Rissanen A. Hakkinen A.M. Tamminen M. et al (2003) Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 52: 701–707.
133. Ueno T. Sugawara H. Sujaku K. Hashimoto O. Tsuji R. Tamaki S. et al (1997) Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27: 103–107.
134. Uygun A. Kadayifci A. Isik A.T. Ozgurtas T. Deveci S. Tuzun A. et al (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19: 537–544.
135. Viljanen A.P. Iozzo P. Borra R. Kankaanpaa M. Karmi A. Lautamaki R. et al (2009) Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metab 94: 50–55.
136. Vuppalanchi R. Chalasani N. (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49: 306–317.
137. Westerbacka J. Lammi K. Hakkinen A.M. Rissanen A. Salminen I. Aro A. et al (2005) Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 90: 2804–2809.
138. Wieckowska A. McCullough A.J. Feldstein A.E. (2007) Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46: 582–589.
139. Williams C.D. Stengel J. Asike M.I. Torres D.M. Shaw J. Contreras M. et al (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140: 124–131.
140. Wong V.W. Vergniol J. Wong G.L. Foucher J. Chan H.L. Le Bail B. et al (2010) Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51: 454–462.
141. Yilmaz Y. Kedrah A.E. Ozdogan O. (2009) Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 15: 4387–4391.
142. Younossi Z.M. Jarrar M. Nugent C. Randhawa M. Afendy M. Stepanova M. et al (2008) A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 18: 1430–1437.
143. Zamor P.J. Russo M.W. (2011) Liver function tests and statins. Curr Opin Cardiol 4: 338–341.
144. Zelber-Sagi S. Kessler A. Brazowsky E. Webb M. Lurie Y. Santo M. et al (2006) A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4: 639–644.